$AADI News

Last published 1y ago

1y agoAADIAadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate UpdatePR NewswireAadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial...
1y agoAADIAadi Bioscience Announces Closing of $100 Million PIPE FinancingPR NewswireAadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to...
1y agoAADIAadi Bioscience Announces Approval of All Proposals at Special Meeting of StockholdersPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...
1y agoAADIAadi Bioscience to Present at the TD Cowen 45th Annual Healthcare ConferencePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5,...
1y agoAADIAadi Bioscience Appoints David Dornan, PhD, as Chief Scientific OfficerPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO). Dr. Dornan ...
1y agoAADIAadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025PR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and...
1y agoAADIAadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE FinancingPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) today announced it has entered into an exclusive license agreement for development and global commercialization...
2y agoAADIAadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) today announced financial results for the third quarter ended September 30, 2024, and provided recent corporate...
2y agoAADIAadi Bioscience to Report Third Quarter 2024 Results and Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) today announced that it will report third quarter 2024 financial results and provide recent corporate updates on ...
2y agoAADIAadi Bioscience Provides PRECISION1 Trial and Corporate UpdatesPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI) today announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid...
2y agoAADIAadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoAADIAadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience to Report Second Quarter 2024 Results and Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience to Participate in the Jefferies Healthcare ConferencePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual MeetingPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience, Inc. (AADI) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoAADIAadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience to Report First Quarter 2024 Results and Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)PR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoAADIAadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage, precision oncology company focused on developing and commercializing therapies for cancers...
2y agoAADIAadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
2y agoAADIAadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024PR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
2y agoAADIAadi Bioscience to Present at the TD Cowen 44th Annual Healthcare ConferencePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
2y agoAADIAadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers SymposiumPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
2y agoAADIAadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers SymposiumPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
2y agoAADIAadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating AlterationsPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...
3y agoAADIAadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically...
3y agoAADIAadi Bioscience to Participate in Jefferies London Healthcare ConferencePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for...
3y agoAADIAadi Bioscience to Report Third Quarter 2023 Results and Operational UpdatePR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for...
3y agoAADIAadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global MeetingPR NewswireAadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with...
3y agoAADIAadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPR NewswireTwo new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial testing nab-sirolimus
3y agoAADIAadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical SymposiumPR NewswireLOS ANGELES, Oct. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today
3y agoAADIAadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)PR NewswireLOS ANGELES, Oct. 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today
3y agoAADIAadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive OfficerPR NewswireDr. Lennon brings over 20 years of pharmaceutical experience, including deep expertise in the development and commercialization of mTOR inhibitors Leadership transition expected to accelerate growth and leverage
3y agoAADIAadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPR NewswireLOS ANGELES, Sept. 20, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today
3y agoAADIAadi Bioscience to Participate at Upcoming Investor ConferencesPR NewswireLOS ANGELES, Sept. 5, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with mTOR pathway
3y agoAADIAadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingPR NewswireLOS ANGELES, May 25, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience to Participate in Upcoming Investor EventsPR NewswireLOS ANGELES, May 23, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic TrialPR NewswireTotal 1Q 2023 revenue on FYARRO® sales of $5.9 million PRECISION 1 tumor agnostic trial enrolling equally in TSC1 and TSC2 arms with more than 15 discreet tumor types represented Interim analysis on 40 patients
3y agoAADIAadi Bioscience to Report First Quarter 2023 Results and Operational UpdatePR NewswireCompany to Host Conference Call and Webcast on Wednesday, May 10, 2023 LOS ANGELES, May 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and
3y agoAADIAadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual MeetingPR NewswireLOS ANGELES, April 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual MeetingPR NewswireLOS ANGELES, April 14, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023PR NewswireLOS ANGELES, April 6, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate UpdatePR NewswireTotal revenue on FYARRO® sales of $15.2 million for FY 2022 PRECISION 1 trial preliminary data expected in the second quarter of 2023 Conference call to be held today at 8:30 am EDT LOS ANGELES, March 28, 2023
3y agoAADIAadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of DirectorsPR NewswireLOS ANGELES, March 27, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's CancerPR NewswireLOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers
3y agoAADIAadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate UpdatePR NewswireCompany to Host Conference Call and Webcast on March 28, 2023 LOS ANGELES, March 15, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on developing and
3y agoAADIAadi Bioscience Announces Leadership TransitionPR NewswireLOS ANGELES, March 3, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ:AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway